Hiram A Gay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2282500/publications.pdf

Version: 2024-02-01

114 papers 4,417 citations

30 h-index 64 g-index

114 all docs

114 docs citations

times ranked

114

5905 citing authors

#	Article	IF	CITATIONS
1	Learning-Based Cancer Treatment Outcome Prognosis Using Multimodal Biomarkers. IEEE Transactions on Radiation and Plasma Medical Sciences, 2022, 6, 231-244.	3.7	1
2	Impact of human papillomavirus on the tumor microenvironment in oropharyngeal squamous cell carcinoma. International Journal of Cancer, 2022, 150, 521-531.	5.1	6
3	Feasibility of Same-Day Prostate Fiducial Markers, Perirectal Hydrogel Spacer Placement, and Computed Tomography and Magnetic Resonance Imaging Simulation for External Beam Radiation Therapy for Low-Risk and Intermediate-Risk Prostate Cancer. Practical Radiation Oncology, 2022, 12, e117-e122.	2.1	5
4	Technical Report: Development and Implementation of an Open Source Template Interpretation Class Library for Automated Treatment Planning. Practical Radiation Oncology, 2022, 12, e153-e160.	2.1	3
5	Propensity-Weighted Survival Analysis of SBRT vs. Conventional Radiotherapy in Unfavorable Intermediate-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2022, 20, 123-131.	1.9	2
6	Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. International Journal of Radiation Oncology Biology Physics, 2022, 112, 83-92.	0.8	6
7	Assessing Inter-Fraction Changes in The Size and Position of The Penile Bulb During Daily MR-Guided Radiation Therapy to The Prostate Bed: Do We Need to Adjust How We Plan Radiation in The Post-Radical Prostatectomy Setting to Reduce Risk of Erectile Dysfunction?. Clinical Genitourinary Cancer. 2022	1.9	1
8	Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-Only versus Whole Pelvic Radiation Therapy. Journal of Urology, 2022, 207, 1227-1235.	0.4	1
9	Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer. Brachytherapy, 2022, , .	0.5	1
10	Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer. European Urology Open Science, 2022, 37, 80-89.	0.4	2
11	Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemotherapy. European Urology Oncology, 2022, 5, 246-250.	5.4	5
12	Reply by Authors. Journal of Urology, 2022, , 101097JU0000000000245502.	0.4	0
13	Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 343-350.e4.	4.9	O
14	Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy. Brachytherapy, 2022, 21, 617-625.	0.5	2
15	A MicroRNA Expression Signature as Prognostic Marker for Oropharyngeal Squamous Cell Carcinoma. Journal of the National Cancer Institute, 2021, 113, 752-759.	6.3	10
16	ARPMâ€net: A novel CNNâ€based adversarial method with Markov random field enhancement for prostate and organs at risk segmentation in pelvic CT images. Medical Physics, 2021, 48, 227-237.	3.0	18
17	nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial. Medical Oncology, 2021, 38, 35.	2.5	11
18	A novel systematic approach for cancer treatment prognosis and its applications in oropharyngeal cancer with microRNA biomarkers. Bioinformatics, 2021, 37, 3106-3114.	4.1	О

#	Article	IF	CITATIONS
19	Modified full-face snorkel mask as COVID-19 personal protective equipment: Quantitative results. HardwareX, 2021, 9, e00185.	2.2	18
20	Abstract CT153: Correlation of <i>CDKN2A</i> genomic alterations with tumor response to palbociclib given before chemoradiation therapy to patients with human papillomavirus-unrelated, locally advanced head and neck squamous-cell carcinoma. Cancer Research, 2021, 81, CT153-CT153.	0.9	1
21	Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis. Clinical and Translational Radiation Oncology, 2021, 29, 47-53.	1.7	0
22	Quantitative Analysis of Practice Size Consolidation in Radiation Oncology: A Trend Toward Bigger and Fewer Practices. Practical Radiation Oncology, 2021, 11, 328-338.	2.1	7
23	Regarding the Use of PSMA PET-CT Versus Conventional Imaging for Assessing the Value of Prophylactic Whole-Pelvis Radiation for High-Risk Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 2847-2848.	1.6	1
24	Semi-supervised semantic segmentation of prostate and organs-at-risk on 3D pelvic CT images. Biomedical Physics and Engineering Express, 2021, 7, 065023.	1.2	5
25	Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. Theranostics, 2021, 11, 9721-9737.	10.0	12
26	A Rational Approach to Unilateral Neck RT for Head and Neck Cancers in the Era of Immunotherapy. Cancers, 2021, 13, 5269.	3.7	1
27	Weaving attention Uâ€net: A novel hybrid CNN and attentionâ€based method for organsâ€ntâ€risk segmentation in head and neck CT images. Medical Physics, 2021, 48, 7052-7062.	3.0	15
28	The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. International Journal of Radiation Oncology Biology Physics, 2021, , .	0.8	9
29	Extranodal extension is a strong prognosticator in HPVâ€positive oropharyngeal squamous cell carcinoma. Laryngoscope, 2020, 130, 939-945.	2.0	56
30	Impact of a SBRT/SRS longitudinal telehealth training pilot course in Latin America. Critical Reviews in Oncology/Hematology, 2020, 154, 103072.	4.4	8
31	A prognostic gene expression signature for oropharyngeal squamous cell carcinoma. EBioMedicine, 2020, 61, 102805.	6.1	16
32	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clinical Cancer Research, 2020, 26, 5140-5152.	7.0	163
33	Who Benefits From a Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial. Practical Radiation Oncology, 2020, 10, 186-194.	2.1	13
34	Review: Brain Metastases in Bladder Cancer. Bladder Cancer, 2020, 6, 237-248.	0.4	4
35	Taking Guatemala From Cobalt to IMRT: A Tale of US Agency Collaboration With Academic Institutions and Industry. International Journal of Radiation Oncology Biology Physics, 2020, 107, 867-872.	0.8	3
36	Management of primary skin cancer during a pandemic: Multidisciplinary recommendations. Cancer, 2020, 126, 3900-3906.	4.1	62

#	Article	IF	Citations
37	Childhood tonsillectomy alters the primary distribution of HPVâ€related oropharyngeal squamous cell carcinoma. Laryngoscope Investigative Otolaryngology, 2020, 5, 210-216.	1.5	7
38	Patterns of care and survival outcomes for laryngeal small cell cancer. Head and Neck, 2019, 41, 722-729.	2.0	2
39	nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma. Medical Oncology, 2019, 36, 93.	2.5	4
40	Favorable long-term toxicity for salvage low-dose rate prostate brachytherapy for recurrent prostate cancer after external beam radiotherapy from a phase II prospective trial (NRG) Tj ETQq0 0 0 rgBT /Ov	erlo d k410 T	f 50o617 Td ((
41	A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database. Clinical and Translational Radiation Oncology, 2019, 15, 38-41.	1.7	17
42	Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural Disaster on Radiation Oncology Patients. Practical Radiation Oncology, 2019, 9, 305-321.	2.1	51
43	Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer. Cancer Medicine, 2019, 8, 3698-3709.	2.8	12
44	Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma. Radiotherapy and Oncology, 2019, 134, 81-88.	0.6	24
45	Impact of Facility Radiation Patient Volume on Overall Survival in Patients with Muscle Invasive Bladder Cancer Undergoing Trimodality Bladder Preservation Therapy. Bladder Cancer, 2019, 5, 235-244.	0.4	6
46	Standardization and automation of quality assurance for high-dose-rate brachytherapy planning with application programming interface. Brachytherapy, 2019, 18, 108-114.e1.	0.5	10
47	Association of Treatment at High-Volume Facilities With Survival in Patients Receiving Chemoradiotherapy for Nasopharyngeal Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 86-89.	2.2	18
48	Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: A propensity score-matched analysis. Advances in Radiation Oncology, 2018, 3, 190-196.	1.2	11
49	Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. Practical Radiation Oncology, 2018, 8, e7-e15.	2.1	43
50	Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database. Journal of Urology, 2018, 199, 416-423.	0.4	36
51	A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. Practical Radiation Oncology, 2018, 8, 40-47.	2.1	27
52	Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder. European Urology Focus, 2018, 4, 900-906.	3.1	30
53	Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapy. Clinical and Translational Radiation Oncology, 2018, 8, 27-39.	1.7	31
54	Radiation Therapy as Definitive Local Treatment in Patients with Limited-Stage Small Cell Carcinoma of the Bladder: Does total dose matter?. Bladder Cancer, 2018, 4, 311-317.	0.4	2

#	Article	IF	CITATIONS
55	Post-operative radiation effects on lymphopenia, neutrophil to lymphocyte ratio, and clinical outcomes in palatine tonsil cancers. Oral Oncology, 2018, 86, 1-7.	1.5	27
56	Predictors of acute throat or esophageal patient reported pain during radiation therapy for head and neck cancer. Clinical and Translational Radiation Oncology, 2018, 13, 1-6.	1.7	1
57	Pretreatment metabolic tumor volume as a prognostic factor in HPVâ€associated oropharyngeal cancer in the context of AJCC 8th edition staging. Head and Neck, 2018, 40, 2280-2287.	2.0	14
58	Induction chemotherapy in the treatment of nasopharyngeal carcinoma: Clinical outcomes and patterns of care. Cancer Medicine, 2018, 7, 3592-3603.	2.8	18
59	Palliative radiation therapy (RT) for prostate cancer patients with bone metastases at diagnosis: A hospitalâ€based analysis of patterns of care, RT fractionation scheme, and overall survival. Cancer Medicine, 2018, 7, 4240-4250.	2.8	10
60	Radiation Therapy for Prostate Cancer. Missouri Medicine, 2018, 115, 146-150.	0.3	7
61	Outcomes of surgically treated human papillomavirus–related oropharyngeal squamous cell carcinoma with <scp>N</scp> 3 disease. Laryngoscope, 2017, 127, 2033-2037.	2.0	6
62	External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. International Journal of Radiation Oncology Biology Physics, 2017, 98, 304-317.	0.8	25
63	Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results ofÂaÂPhase III Trial. International Journal of Radiation Oncology Biology Physics, 2017, 97, 976-985.	0.8	276
64	Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma. Head and Neck Pathology, 2017, 11, 338-345.	2.6	9
65	Comparison of unilateral versus bilateral intensityâ€modulated radiotherapy for surgically treated squamous cell carcinoma of the palatine tonsil. Cancer, 2017, 123, 4594-4607.	4.1	46
66	nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma. Oral Oncology, 2017, 72, 26-31.	1.5	12
67	Two-and-a-half-year clinical experience with the world's first magnetic resonance image guided radiation therapy system. Advances in Radiation Oncology, 2017, 2, 485-493.	1.2	128
68	Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall. Practical Radiation Oncology, 2017, 7, 195-202.	2.1	62
69	Reevaluation of postoperative radiation dose in the management of human papillomavirus–positive oropharyngeal cancer. Head and Neck, 2016, 38, 1643-1649.	2.0	18
70	A comparative study based on image quality and clinical task performance for CT reconstruction algorithms in radiotherapy. Journal of Applied Clinical Medical Physics, 2016, 17, 377-390.	1.9	11
71	An integrated model-driven method for in-treatment upper airway motion tracking using cine MRI in head and neck radiation therapy. Medical Physics, 2016, 43, 4700-4710.	3.0	14
72	Does elimination of planned postoperative radiation to the primary bed in p16-positive, transorally-resected oropharyngeal carcinoma associate with poorer outcomes?. Oral Oncology, 2016, 61, 127-134.	1.5	20

#	Article	IF	CITATIONS
73	Functional Data Analysis Applied to Modeling of Severe Acute Mucositis and Dysphagia Resulting From Head and Neck Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 820-831.	0.8	14
74	nab -Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. Oral Oncology, 2016, 61, 1-7.	1.5	18
75	Prognostic micro <scp>RNA</scp> signatures derived from The Cancer Genome Atlas for head and neck squamous cell carcinomas. Cancer Medicine, 2016, 5, 1619-1628.	2.8	86
76	High E6 Gene Expression Predicts for Distant Metastasis and Poor Survival in Patients With HPV-Positive Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1132-1141.	0.8	25
77	Nabâ€paclitaxelâ€based compared to docetaxelâ€based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck. Cancer Medicine, 2015, 4, 481-489.	2.8	18
78	Automated contouring error detection based on supervised geometric attribute distribution models for radiation therapy: A general strategy. Medical Physics, 2015, 42, 1048-1059.	3.0	45
79	Late gastrointestinal tissue effects after hypofractionated radiation therapy of the pancreas. Radiation Oncology, 2015, 10, 186.	2.7	36
80	Outcomes of P16 positive oropharyngeal squamous cell carcinoma treated with surgery and adjuvant IMRT. Journal of Radiation Oncology, 2015, 4, 37-46.	0.7	0
81	Magnetic resonance imaging-based treatment planning for prostate cancer: Use of population average tissue densities within the irradiated volume to improve plan accuracy. Practical Radiation Oncology, 2015, 5, 248-256.	2.1	6
82	Treatment Outcomes for T4 Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 1118.	2.2	33
83	High metastatic node number, not extracapsular spread or N-classification is a node-related prognosticator in transorally-resected, neck-dissected p16-positive oropharynx cancer. Oral Oncology, 2015, 51, 514-520.	1.5	120
84	Pre-radiotherapy feeding tube identifies a poor prognostic subset of postoperative p16 positive oropharyngeal carcinoma patients. Radiation Oncology, 2015, 10, 8.	2.7	6
85	Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: DosimetricÂand Clinical Effects of Perirectal Spacer Application in Men Undergoing ProstateÂlmage Guided Intensity Modulated RadiationÂTherapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 971-977.	0.8	285
86	Automatic CT simulation optimization for radiation therapy: A general strategy. Medical Physics, 2014, 41, 031913.	3.0	9
87	Physician Attitudes and Practices Related to Voluntary Error and Near-Miss Reporting. Journal of Oncology Practice, 2014, 10, e350-e357.	2.5	39
88	Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer. Lung Cancer, 2014, 83, 67-72.	2.0	1
89	Transperineal ultrasound-guided implantation of electromagnetic transponders in the prostatic fossa for localization and tracking during external beam radiation therapy. Practical Radiation Oncology, 2014, 4, 415-421.	2.1	4
90	Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer. Practical Radiation Oncology, 2014, 4, 430-436.	2.1	16

#	Article	IF	Citations
91	A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma. Cancer, 2013, 119, 72-80.	4.1	67
92	Improve definition of titanium tandems in MR-guided high dose rate brachytherapy for cervical cancer using proton density weighted MRI. Radiation Oncology, 2013, 8, 16.	2.7	20
93	Prognostic value of 18F-FDG PET metabolic parameters in oropharyngeal squamous cell carcinoma. Journal of Radiation Oncology, 2013, 2, 27-34.	0.7	30
94	Multi-institutional Quantitative Evaluation and Clinical Validation of Smart Probabilistic Image Contouring Engine (SPICE) Autosegmentation of Target Structures and Normal Tissues on Computer Tomography Images in the Head and Neck, Thorax, Liver, and Male Pelvis Areas. International Journal of Radiation Oncology Biology Physics, 2013, 87, 809-816.	0.8	34
95	Utility of Normal Tissue-to-Tumor $\hat{l}\pm\hat{l}^2$ Ratio When Evaluating Isodoses of Isoeffective Radiation Therapy Treatment Plans. International Journal of Radiation Oncology Biology Physics, 2013, 85, e81-e87.	0.8	19
96	A phase 2 trial of induction ⟨i⟩nab⟨ i⟩â€paclitaxel and cetuximab given with cisplatin and 5â€fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. Cancer, 2013, 119, 766-773.	4.1	31
97	Reply. Urology, 2013, 82, 1369.	1.0	0
98	An Evaluation of Departmental Radiation Oncology Incident Reports: Anticipating a National Reporting System. International Journal of Radiation Oncology Biology Physics, 2013, 85, 919-923.	0.8	40
99	Adaptive Radiation Therapy for Postprostatectomy Patients Using Real-Time Electromagnetic Target Motion Tracking During External Beam Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1038-1044.	0.8	33
100	A novel RTâ€PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis. International Journal of Cancer, 2013, 132, 882-890.	5.1	91
101	Modeling of Non-Small Cell Lung Cancer Volume Changes during CT-Based Image Guided Radiotherapy: Patterns Observed and Clinical Implications. Computational and Mathematical Methods in Medicine, 2013, 2013, 1-13.	1.3	4
102	Clinical evaluation of a commercial orthopedic metal artifact reduction tool for CT simulations in radiation therapy. Medical Physics, 2012, 39, 7507-7517.	3.0	103
103	Pelvic Normal Tissue Contouring Guidelines for Radiation Therapy: A Radiation Therapy Oncology Group Consensus Panel Atlas. International Journal of Radiation Oncology Biology Physics, 2012, 83, e353-e362.	0.8	412
104	Quality Control Quantification (QCQ): A Tool to Measure the Value of Quality Control Checks in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2012, 84, e263-e269.	0.8	136
105	Total error shift patterns for daily CT on rails image-guided radiotherapy to the prostate bed. Radiation Oncology, 2011, 6, 142.	2.7	12
106	Radiation Dose–Volume Effects in Radiation-Induced Rectal Injury. International Journal of Radiation Oncology Biology Physics, 2010, 76, S123-S129.	0.8	621
107	Identification and Management of Persistently Active Brachytherapy Seed Implants. American Journal of Roentgenology, 2009, 193, W403-W406.	2.2	1
108	Identification of extracellular δâ€catenin accumulation for prostate cancer detection. Prostate, 2009, 69, 411-418.	2.3	101

#	Article	IF	CITATIONS
109	PDT for cancers of the head and neck. Photodiagnosis and Photodynamic Therapy, 2009, 6, 1-2.	2.6	8
110	Isodose-based methodology for minimizing the morbidity and mortality of thoracic hypofractionated radiotherapy. Radiotherapy and Oncology, 2009, 91, 369-378.	0.6	16
111	A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy. Physica Medica, 2007, 23, 115-125.	0.7	249
112	Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy. Dermatology Online Journal, 2007, 13, 6.	0.5	9
113	Image-guided radiation therapy: current and future directions. Future Oncology, 2006, 2, 477-492.	2.4	17
114	Malignant parotid tumors: Presentation, clinical/pathologic prognostic factors, and treatment outcomes. International Journal of Radiation Oncology Biology Physics, 2005, 61, 112-118.	0.8	99